A recent study using 2017–2018 NHANES data reveals that 41.9% of the US population suffers from metabolic-associated fatty liver disease (MAFLD), affecting both obese (28.6%) and non-obese (13.4%) individuals. Among those with MAFLD, 67.1% were obese, while 32.9% were non-obese. Obese MAFLD is more prevalent in Blacks, while non-obese MAFLD is more frequent in Asians. Individuals with obese MAFLD exhibit more advanced fibrosis and metabolic comorbidities. The study emphasizes the significant role of high-quality diet and physical activity in reducing the risk of both obese and non-obese MAFLD.
Like
Save
Share